Cancer Treatment Market Research Reports & Industry Analysis
Cancer is a disease characterized by uncontrolled cell proliferation. Of the more than 100 types of cancer, lung, breast, and colorectal cancer account for nearly half of new cases per year in the United States. Lung cancer, which is highly correlated with cigarette smoking, is responsible for more deaths than any other form of cancer. Cigarette smoking and other environmental factors are associated with the majority of cancers.
With the growing incidence of cancer, a growing and aging world population and significant medical advances, there will continue to be phenomenal growth in the market for cancer diagnosis and treatment products.
Cancer Treatment Industry Research & Market Reports
-
Cancer Supportive Care
... at a CAGR of 2.2% over the analysis period 2024-2030. Opioids, one of the segments analyzed in the report, is expected to record a 2.3% CAGR and reach US$11.1 Billion by the end of the ... Read More
-
Kaposi Sarcoma
... CAGR of 3.2% over the analysis period 2024-2030. HAART, one of the segments analyzed in the report, is expected to record a 3.2% CAGR and reach US$101.5 Million by the end of the analysis period. ... Read More
-
Lung Cancer Surgery
... at a CAGR of 4.2% over the analysis period 2024-2030. Thoracotomy, one of the segments analyzed in the report, is expected to record a 4.1% CAGR and reach US$5.8 Billion by the end of the ... Read More
-
Non-Hodgkin Lymphoma Therapeutics
... at a CAGR of 7.0% over the analysis period 2024-2030. Immunotherapy, one of the segments analyzed in the report, is expected to record a 7.5% CAGR and reach US$10.1 Billion by the end of the ... Read More
-
Basal Cell Carcinoma Treatment
... 2030, growing at a CAGR of 8.1% over the analysis period 2024-2030. Surgery, one of the segments analyzed in the report, is expected to record a 8.7% CAGR and reach US$7.6 Billion by the end ... Read More
-
Endometrial Cancer Treatment
... at a CAGR of 5.0% over the analysis period 2024-2030. Chemotherapy, one of the segments analyzed in the report, is expected to record a 4.7% CAGR and reach US$31.3 Billion by the end of the ... Read More
-
Gynecological Cancer Drugs
... at a CAGR of 5.1% over the analysis period 2024-2030. Cervical Cancer, one of the segments analyzed in the report, is expected to record a 5.7% CAGR and reach US$10.3 Billion by the end of ... Read More
-
Particle Therapy
... CAGR of 8.8% over the analysis period 2024-2030. Proton Therapy, one of the segments analyzed in the report, is expected to record a 9.2% CAGR and reach US$2.3 Billion by the end of the analysis ... Read More
-
Prostate Cancer Diagnostics
... at a CAGR of 13.3% over the analysis period 2024-2030. Preliminary, one of the segments analyzed in the report, is expected to record a 12.6% CAGR and reach US$10.0 Billion by the end of the ... Read More
-
Breast Cancer Liquid Biopsy
... 2030, growing at a CAGR of 21.9% over the analysis period 2024-2030. Reagent Kits, one of the segments analyzed in the report, is expected to record a 22.4% CAGR and reach US$819.3 Million by the ... Read More
-
Cancer Immunotherapy Drug Discovery Outsourcing
... Billion by 2030, growing at a CAGR of 14.0% over the analysis period 2024-2030. Monoclonal Antibodies, one of the segments analyzed in the report, is expected to record a 13.4% CAGR and reach US$1.5 Billion ... Read More
-
Doxorubicin
... 5.8% over the analysis period 2024-2030. Breast Cancer, one of the segments analyzed in the report, is expected to record a 5.6% CAGR and reach US$374.1 Million by the end of the analysis period. Growth ... Read More
-
Genomics in Cancer Care
... 2030, growing at a CAGR of 16.7% over the analysis period 2024-2030. Instruments, one of the segments analyzed in the report, is expected to record a 15.4% CAGR and reach US$25.0 Billion by the end ... Read More
-
Immunomodulators
... 5.7% over the analysis period 2024-2030. Immunosuppressants, one of the segments analyzed in the report, is expected to record a 6.1% CAGR and reach US$209.8 Million by the end of the analysis period. Growth in ... Read More
-
Microwave Ablation
... CAGR of 13.2% over the analysis period 2024-2030. Liver Cancer, one of the segments analyzed in the report, is expected to record a 15.2% CAGR and reach US$215.5 Million by the end of the analysis ... Read More
-
In-Vitro Colorectal Cancer Screening Tests
... Billion by 2030, growing at a CAGR of 3.3% over the analysis period 2024-2030. Fecal Occult Blood Test, one of the segments analyzed in the report, is expected to record a 3.8% CAGR and reach ... Read More
-
Chronic Myelogenous Leukemia Treatment
... 2030, growing at a CAGR of 5.3% over the analysis period 2024-2030. Disease Specific Treatment, one of the segments analyzed in the report, is expected to record a 6.0% CAGR and reach US$3.4 Billion by ... Read More
-
Head and Neck Cancer Therapeutics
... Billion by 2030, growing at a CAGR of 5.7% over the analysis period 2024-2030. PD Inhibitors, one of the segments analyzed in the report, is expected to record a 7.8% CAGR and reach US$2.5 Billion ... Read More
-
Intraoperative Radiation Therapy
... at a CAGR of 6.0% over the analysis period 2024-2030. Systems / Accelerators, one of the segments analyzed in the report, is expected to record a 7.1% CAGR and reach US$22.9 Million by the end ... Read More
-
Next Generation Cancer Diagnostics
... 2030, growing at a CAGR of 21.8% over the analysis period 2024-2030. qPCR & Multiplexing, one of the segments analyzed in the report, is expected to record a 22.8% CAGR and reach US$28.2 Billion by ... Read More
-
Sarcoma Drugs
... CAGR of 7.6% over the analysis period 2024-2030. Targeted Therapy, one of the segments analyzed in the report, is expected to record a 7.4% CAGR and reach US$1.9 Billion by the end of the analysis ... Read More
-
Urothelial Cancer Drugs
... at a CAGR of 20.7% over the analysis period 2024-2030. Immunotherapy, one of the segments analyzed in the report, is expected to record a 20.3% CAGR and reach US$13.3 Billion by the end of the ... Read More
-
mRNA Platform
... CAGR of -2.7% over the analysis period 2024-2030. Covid-19 Vaccine, one of the segments analyzed in the report, is expected to record a -6.3% CAGR and reach US$102.1 Billion by the end of the analysis ... Read More
-
Lung Cancer Diagnostics
... at a CAGR of 7.8% over the analysis period 2024-2030. Imaging Tests, one of the segments analyzed in the report, is expected to record a 7.4% CAGR and reach US$2.3 Billion by the end of ... Read More
-
Tumor / Cancer Markers
... 2030, growing at a CAGR of 6.4% over the analysis period 2024-2030. The U.S. Market is Estimated at US$1.2 Billion While China is Forecast to Grow at 10.4% CAGR The Tumor / Cancer Markers market ... Read More
Research Assistance
